• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Purple Biotech Ltd.

    4/22/25 4:30:17 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PPBT alert in real time by email
    6-K 1 ea0239112-6k_purple.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16

    of the Securities Exchange Act of 1934

     

    For the month of April 2025

     

    Commission File Number: 001-37643

     

    PURPLE BIOTECH LTD.

    (Translation of registrant’s name into English)

     

    4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒        Form 40-F ☐

     

     

     

     

     

     

    Purple Biotech Ltd. (the “Company” or the “Registrant”) is announcing the results of the Annual General Meeting of Shareholders of the Company held on April 22, 2025, at the Company’s offices (the “Meeting”). At the Meeting, the shareholders of the Company voted on the proposals described in the Company’s Proxy Statement for the Meeting that was attached as Exhibit 99.1 to a Report of Foreign Private Issuer on Form 6-K furnished by the Company to the U.S. Securities and Exchange Commission on February 28, 2025 (the “Proxy Statement”).

     

    Each of the proposals presented for approval at the Meeting was approved by the requisite vote of the Company’s shareholders in accordance with the Israeli Companies Law, 5759-1999 and the Company’s articles of association, as described in the Proxy Statement, other than Proposals 2(a) and 2(b), which were not supported by the Company’s shareholders.

     

    Accordingly, at the Meeting, the shareholders approved the following proposals:

     

    (i)Prospal 1(a): The re-election of Eric Rowinsky to serve as a first class director, until the annual general meeting to be held in 2028, and until his successor is duly elected and qualified.

     

    (ii)Proposal 1(b): the re-election of Robert Gagnon to serve as a first class director, until the annual general meeting to be held in 2028, and until his successor is duly elected and qualified.

     

    (iii)Proposal 1(c): The re-election of Ido Agmon to serve as a first class director, until the annual general meeting to be held in 2028, and until his successor is duly elected and qualified.

     

    (iv)Proposal 3: An increase of the Company’s authorized ordinary share capital from 1,000,000,000 ordinary shares, with no par value, to 100,000,000,000 ordinary shares, with no par value, and to amend Article 11 of the Company’s Articles of Association accordingly.

     

    Incorporation by Reference

     

    This Report on Form 6-K, including all exhibits attached hereto, is hereby incorporated by reference into each of the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant’s Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 28, 2019 (Registration file number 333-230584), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrant’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission on December 27, 2019 (Registration file number 333-235729), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on May 13, 2020 (Registration file number 333-238229), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 18, 2020 (Registration file number 333-238481), each of the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange Commission on July 10, 2020 (Registration file numbers 333-239807 and 333-233793), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on April 4, 2022 (Registration file number 333-264107) and the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on March 23, 2023 (Registration file number 333-270769), the Registrant’s Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on December 8, 2022 (Registration file number 333-268710), the Registrant’s Registration Statement on Form F-1, as amended, originally filed with the Securities and Exchange Commission on October 30, 2023 (Registration file number 333-275216) and the Registrant’s Registration Statement on Form F-1, filed with the Securities and Exchange Commission on July 22, 2024 (Registration file number 333-280947), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

     

    April 22, 2025 PURPLE BIOTECH LTD.
         
      By: /s/ Gil Efron
        Gil Efron
        Chief Executive Officer

     

     

    2

     

    Get the next $PPBT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PPBT

    DatePrice TargetRatingAnalyst
    More analyst ratings